Emapalumab

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dermatomyositis

Conditions

Dermatomyositis, Dermatomyositis Sine Myositis, Dermatomyositis With Myopathy, Dermatomyositis With Respiratory Involvement, Dermatomyositis With Organ Involvement, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)

Trial Timeline

May 1, 2026 → May 1, 2027

NCT ID

NCT07486869

About Emapalumab

Emapalumab is a phase 2 stage product being developed by Swedish Orphan Biovitrum for Dermatomyositis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07486869. Target conditions include Dermatomyositis, Dermatomyositis Sine Myositis, Dermatomyositis With Myopathy.

What happened to similar drugs?

0 of 3 similar drugs in Dermatomyositis were approved

Approved (0) Terminated (1) Active (2)

🔄DazukibartPfizerPhase 3

❌human immunoglobulin G + PlaceboCSLPhase 3

🔄Lenabasum 20 mg + Lenabasum 5 mg + PlaceboCorbus PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07486869	Phase 2	Recruiting	May 1, 2026	May 1, 2027	Dermatomyositis
NCT05001737	Phase 3	Completed	Dec 15, 2021	Jun 4, 2025	Macrophage Activation Syndrome
NCT04731298	Phase 2	Terminated	May 25, 2021	Apr 21, 2022	Graft Failure
NCT03312751	Phase 3	Completed	Feb 6, 2019	Sep 14, 2022	Primary Hemophagocytic Lymphohistiocytosis
NCT03311854	Phase 2	Completed	Feb 20, 2018	May 19, 2020	Macrophage Activation Syndrome
NCT02069899	Phase 2/3	Completed	Aug 4, 2014	May 18, 2021	Hemophagocytic Lymphohistiocytosis

Competing Products

14 competing products in Dermatomyositis

See all competitors

Product	Company	Stage	Hype Score
tacrolimus	Astellas Pharma	Pre-clinical	26
M5049 high dose + Placebo	Merck	Phase 2	27
BAF312 + Placebo	Novartis	Phase 2	27
MEDI7734 + Placebo	Amgen	Phase 1	29
Etanercept + Placebo	Amgen	Phase 1	29
Dazukibart	Pfizer	Phase 3	47
Anti-Beta Interferon (PF-06823859)	Pfizer	Phase 2	35
PF-06823859 low + Placebo Arm + PF-06823859 high	Pfizer	Phase 2	35
Tofacitinib	Pfizer	Phase 1	29
human immunoglobulin G + Placebo	CSL	Phase 3	32
Empasiprubart IV	Argenx	Phase 2	36
GLPG3667 + Placebo	Galapagos	Phase 2	33
Lenabasum 20 mg + Lenabasum 5 mg + Placebo	Corbus Pharmaceuticals	Phase 3	30
JBT-101 + Placebo	Corbus Pharmaceuticals	Phase 2	17